Myricetin.

Myricetin and quercetin are flavonols cleared by the same intestinal glucuronidation and sulfation steps. Taken together they compete for that conjugating capacity, so circulating levels of each can run higher than either does alone.

When myricetin quenches a radical it becomes a phenoxyl radical itself. Ascorbate donates an electron back and returns the flavonol to its reduced form, which is why polyphenols and vitamin C are placed together in antioxidant blends.

Alpha-tocopherol handles radicals inside the lipid membrane and myricetin works at the water and lipid interface. The flavonol can regenerate the tocopheroxyl radical, so tocopherol is consumed more slowly.

The hydroxyl pattern on myricetin binds ferric iron in the gut lumen and forms a complex the intestine takes up poorly. Taking a flavonol-rich extract in the same sitting as a non-heme iron dose lowers how much of that iron is absorbed.

Myricetin binds copper ions through its adjacent hydroxyl groups. That lowers free copper available for absorption and also changes whether the flavonol behaves as an antioxidant or as a metal-driven pro-oxidant.

Flavonols like myricetin are heavily glucuronidated in the gut wall before they reach the circulation. Piperine slows that conjugation step, so a given dose can produce higher and longer-lasting blood levels.

Fisetin and myricetin share the flavonol backbone and the same sulfotransferase and UGT clearance route. Stacking them raises total flavonol exposure rather than adding an independent mechanism.

Both carry a pyrogallol ring and are handled by the same COMT, sulfotransferase and UGT enzymes. Co-dosing means each occupies part of the shared clearance capacity, so exposure to both can run higher than the doses alone would predict.

Myricetin and resveratrol are both heavily glucuronidated and sulfated in the intestinal wall and liver. When the two arrive together they compete for the same UGT and SULT capacity, which can raise the unconjugated fraction of whichever is present in smaller amounts. The direction and size of that shift depend on dose and timing and have not been characterised in humans for this specific pair. Formulators pair them for overlapping antioxidant chemistry rather than for a measured interaction.

Pterostilbene carries two methoxy groups that slow its conjugation, while myricetin is conjugated quickly. Blends put them together so that a slower and a faster clearing polyphenol are both present after a single dose. This is a formulation rationale drawn from each compound's metabolism, not a co-administration trial.

Luteolin and myricetin both carry catechol or pyrogallol hydroxylation patterns that let them donate hydrogen atoms to peroxyl radicals. In mixed plant foods they occur together and are absorbed by the same intestinal routes. Any combined effect is inferred from shared chemistry and has not been measured for the pair on its own.

Both reach the small intestine mostly as glycosides and depend on lactase phlorizin hydrolase and cytosolic beta-glucosidase before the aglycone can cross the enterocyte. Loading both at once places demand on the same limited hydrolysis and conjugation steps. Whether that meaningfully changes plasma levels of either has not been quantified.

Rutin and myricetin are frequently isolated from the same plant fractions and are handled by the same glycoside hydrolysis and microbial ring fission routes. Colonic bacteria degrade both to small phenolic acids that appear in plasma long after the parent compounds have cleared. The pairing is a plant matrix reality rather than a tested combination.

Once myricetin donates a hydrogen atom it becomes an aryloxyl radical that must be reduced back or it is lost. Dihydrolipoic acid, the reduced form of alpha-lipoic acid, is a strong enough reductant to regenerate oxidised phenolics in model systems. This chemistry is well described in vitro; the extent to which it happens at supplement doses in people is not established.

Cellular glutathione both regenerates oxidised phenolic radicals and serves as the conjugation partner when a flavonoid quinone forms. Myricetin's pyrogallol ring can oxidise to a quinone that reacts with glutathione, which consumes thiol pool at high concentrations. So the relationship runs in two directions: glutathione supports myricetin's antioxidant turnover, and heavy myricetin oxidation draws on glutathione.

N-acetylcysteine delivers cysteine, the rate-limiting amino acid for glutathione synthesis. Where a polyphenol undergoes redox cycling and forms reactive quinones, an intact glutathione pool is what conjugates them. The link is mechanistic biochemistry rather than a trial of the two together.

Myricetin carries catechol and pyrogallol hydroxyls plus a 3-hydroxy-4-keto arrangement, all classic metal binding sites. In the gut lumen those sites can bind zinc and form complexes that are less available for uptake. Separating a high polyphenol dose from a zinc dose by a couple of hours is the usual formulation answer.

Calcium binds less avidly to flavonols than iron or copper do, but at the gram doses used for calcium the complexation still occurs. The practical consequence is that a large calcium load and a concentrated flavonol extract taken together may each be less available. Dose separation is the simple workaround.

Myricetin is barely soluble in water and its absorption is limited by dissolution before metabolism ever becomes the constraint. Forming a phospholipid complex gives the molecule an amphiphilic carrier that disperses in intestinal fluid. The approach is established for several flavonoids; the size of the gain differs by compound and by manufacturing method.

Lecithin supplies phosphatidylcholine and related phospholipids that emulsify a lipophilic flavonol into mixed micelles. That keeps the compound in solution through the length of the small intestine rather than precipitating. The pairing is formulation practice grounded in solubility chemistry.

Medium chain triglycerides are liquid at body temperature and stimulate bile release, both of which help disperse a poorly soluble solid. Myricetin's absorption is dissolution limited, so the vehicle matters. No human pharmacokinetic study of this specific pairing has been done.

Most of an oral myricetin dose is never absorbed intact and instead reaches the colon, where bacterial enzymes cleave the C ring into smaller phenolic acids that do enter circulation. A fermentable substrate such as inulin shifts which bacteria are abundant and therefore which metabolites appear. A mouse study reported that myricetin's effects on hepatic lipid handling tracked with changes in gut microbiota composition.

Bacterial beta-glucosidases release the aglycone from plant glycosides, and other species open the flavonol ring to give phenolic acids. Which organisms are present changes both the rate and the products. Whether a given probiotic strain shifts myricetin metabolism in people has not been measured.

Myricetin occurs in food mostly as glycosides such as myricitrin, and the sugar has to come off before the aglycone can cross a membrane. Lactobacillus plantarum expresses glycosidases that perform this step in culture. Extrapolating from culture to the human colon is an assumption, not a finding.

Curcumin is a potent inhibitor of intestinal glucuronidation, and myricetin depends on that same pathway for clearance. Taking them together could raise unconjugated myricetin, though nobody has measured it. Read this as mechanistic reasoning rather than a clinical observation.

Glutathione peroxidase requires a selenocysteine residue, and it is the enzyme that clears the hydroperoxides a phenolic antioxidant cannot handle alone. The two act at different points of the same antioxidant network. This is network reasoning; no trial has combined them.